Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has appointed Evan Ballantyne as CFO, effective March 1. He succeeds Donato Spota, who, as previously reported, will leave the company on February 28….
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has appointed Evan Ballantyne as CFO, effective March 1. He succeeds Donato Spota, who, as previously reported, will leave the company on February 28….
…
…